(March 1, 2019) OCRA mourns the loss of our beloved board member and friend, Lori Newcomb. We are profoundly grateful for her vision and dedication in creating Newk’s Cares along with her loving husband, Chris, to support ovarian cancer research through their family business, Newk’s Eatery. Her unwavering and selfless commitment to help other women and to find a cure for this terrible disease is a testament to her incredible character. And her feisty, funny and infectious personality that shined so brightly will be sorely missed. Lori’s dedication and work to end ovarian cancer will live on through her legacy and will one day ensure that no other woman has to endure this terrible disease. Sending our love to Chris, Madison, Blair and Hayes.
Related Topics
OCRA President & CEO Audra Moran Named Crain’s 2026 Notable Leader in Health Care
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued